SFM
ELDN icon

Sphera Funds Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Sphera Funds Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,200
Closed -$84.6K – 121
2025
Q2 		$84.6K Buy
+31,200
New +$93.6K 0.02% 108

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's ELDN Position: Q1 2026 in Review

Sphera Funds Management reduced its Eledon Pharmaceuticals (ELDN) stake by 17% in Q1 2026, selling an estimated $848K and leaving 1,772,131 shares worth $5.46M. The position accounts for 0.87% of the portfolio, ranked #42.

Sphera Funds Management first reported a position in ELDN in Q3 2014 and has held it in 11 quarters since. The position peaked at $10.5M in Q4 2024. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Sphera Funds Management held 1,772,131 shares of Eledon Pharmaceuticals worth $5.46M as of Q1 2026.
  • Sphera Funds Management sold 360,000 Eledon Pharmaceuticals shares in Q1 2026, an estimated $848K.
  • Eledon Pharmaceuticals made up 0.87% of Sphera Funds Management's portfolio in Q1 2026, its #42 holding.
  • Sphera Funds Management first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 11 quarters since.
  • Sphera Funds Management's Eledon Pharmaceuticals position peaked at $10.5M in Q4 2024.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.